Clinical trial
A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Setanaxib, When Administered With Pembrolizumab, in Patients With Recurrent or Metastatic SCCHN
NCT05323656 is registered in ClinicalTrials.gov with Calliditas Therapeutics Suisse SA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Setanaxib, When Administered With Pembrolizumab, in Patients With Recurrent or Metastatic SCCHN
- Lead sponsor
- Calliditas Therapeutics Suisse SA
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 6, 2022
- Completion date
- August 21, 2025
- Enrollment
- 55 (actual)
- Sites
- 24
Conditions
As the registry lists them; a condition with its own page is linked.